Surprise, Surprise: New Study Slams Miracle Drug Trump Was Pushing
A new study has totally debunked any effectiveness that hydroxychloroquine, the ani-malaria drug that Trump was pushing hard as a form of treating coronavirus, had no benefit whatsoever according to an analysis of those hospitalized in Veterans Health Administration medical centers.
The study found but two outcomes for COVID-19 patients treated with hydroxychloroquine: death and the need for mechanical ventilation. It was conducted retrospectively and relied on data from patients hospitalized with confirmed coronavirus infections in all Veterans Health Administration medical centers until April 11.
Although the study only looked at 368 patients, it represented the largest look at the outcomes of COVID-19 patients receiving treated from hydroxychloroquine — with or without azithromycin, a common antibiotic — anywhere in the world.
President Trump was selling this mystery drug as though it were vitamin tonic, however, and even had a financial interest in the drug. Many randomized trials of hydroxychloroquine are currently underway and will eventually provide even more information about its safety and efficacy.
Hydroxychloroquine, long touted by President Trump, is of no use treating Covid-19 and actually causes more deaths than standard care, per a large new study. https://t.co/eCpEH9DGS0
— Ben White (@morningmoneyben) April 21, 2020
“However, given its increasingly widespread use, not only as therapy but also as prophylaxis for COVID-19, there is a great and immediate need to obtain insights into the clinical outcomes among patients currently treated with hydroxychloroquine, particularly because of the non-negligible toxicities associated with its use,” the authors wrote.
Complicating matters is the fact that hydroxychloroquine hasn’t gotten much-needed peer-review, thus making any evidence largely anecdotal. Hospitals have widely administered the drug to patients with COVID-19 in the hope that it would help, but there doesn’t exist any real evidence of its effectiveness as pointed out in the study.
Notwithstanding, the Food and Drug Administration used its emergency powers to grant hospitals and providers the use of hydroxychloroquine for COVID-19 in situations where clinical trials are unavailable or infeasible.